HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

An antibody-drug conjugate targeting the endothelin B receptor for the treatment of melanoma.

AbstractPURPOSE:
To identify and evaluate targets amenable to antibody therapy in melanoma.
EXPERIMENTAL DESIGN:
We searched for mRNA transcripts coding for cell-surface proteins with expression patterns similar to that of the melanoma oncogene MITF. One such candidate, the endothelin B receptor (EDNBR), was first analyzed for a functional contribution to tumor growth by conditional induction of shRNA. Second, antibodies were raised to the receptor, conjugated with monomethyl auristatin E, and tested for efficacy against melanoma tumor models generated from cell lines.
RESULTS:
Conditional knockdown of the receptor in tumor xenograft models resulted in only a modest impact on tumor growth. A monoclonal antibody reactive with the N-terminal tail of EDNBR was found to internalize rapidly into melanoma cells. When conjugated with monomethyl auristatin E, the antibody-drug conjugate (ADC) showed remarkable efficacy against human melanoma cell lines and xenograft tumor models that was commensurate with levels of receptor expression. Comparative immunohistochemistry revealed a range of EDNBR expression across a panel of human melanomas, with the majority expressing levels equivalent to or greater than that in the models responsive to the ADC.
CONCLUSION:
An ADC targeting the EDNBR is highly efficacious in preclinical models of melanoma.
AuthorsJyoti Asundi, Chae Reed, Jennifer Arca, Krista McCutcheon, Ronald Ferrando, Suzanna Clark, Elizabeth Luis, Janet Tien, Ron Firestein, Paul Polakis
JournalClinical cancer research : an official journal of the American Association for Cancer Research (Clin Cancer Res) Vol. 17 Issue 5 Pg. 965-75 (Mar 01 2011) ISSN: 1557-3265 [Electronic] United States
PMID21245091 (Publication Type: Journal Article)
Copyright©2011 AACR.
Chemical References
  • Antibodies, Monoclonal
  • Antineoplastic Agents
  • Endothelin B Receptor Antagonists
  • Immunoconjugates
  • Microphthalmia-Associated Transcription Factor
  • Oligopeptides
  • RNA, Messenger
  • Receptor, Endothelin B
  • monomethyl auristatin E
Topics
  • Animals
  • Antibodies, Monoclonal (therapeutic use)
  • Antineoplastic Agents (therapeutic use)
  • Blotting, Western
  • Cell Line, Tumor
  • Endothelin B Receptor Antagonists
  • Flow Cytometry
  • Fluorescent Antibody Technique
  • Gene Expression
  • Gene Knockdown Techniques
  • Humans
  • Immunoconjugates (therapeutic use)
  • Macaca fascicularis
  • Melanoma (drug therapy, genetics, immunology)
  • Melanoma, Experimental (drug therapy, genetics, immunology)
  • Mice
  • Mice, Inbred BALB C
  • Microphthalmia-Associated Transcription Factor (genetics)
  • Oligopeptides (administration & dosage, therapeutic use)
  • RNA, Messenger (genetics, metabolism)
  • Rats
  • Receptor, Endothelin B (immunology)
  • Xenograft Model Antitumor Assays

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: